Ahmed Abdulrahman Al Mathehaji: LMWH Is Preferred Despite Elevated INR in Decompensated Cirrhosis
Ahmed Abdulrahman Al Mathehaji, Internal Medicine Specialist and Gastroenterology, Hepatology, Endoscopy Fellow, shared a post on X:
“Low molecular weight heparin (LMWH) is the preferred anticoagulant for treating acute deep vein thrombosis in patients with decompensated cirrhosis, regardless of the elevated INR.
The elevated INR should not be considered an absolute contraindication to anticoagulation, as it reflects impaired hepatic synthetic function rather than true anticoagulation status in cirrhosis.
Direct oral anticoagulants (DOACs) are contraindicated in decompensated cirrhosis, particularly in Child-Pugh class C patients and critically ill individuals, due to hepatic metabolism and unpredictable drug levels.
While DOACs may be considered in compensated cirrhosis (Child-Pugh class A or B), they should be avoided in decompensated disease.
LMWH has demonstrated superior outcomes in cirrhotic patients with venous thromboembolism, achieving higher recanalization rates (71% vs 42% without treatment) and lower variceal bleeding risk compared to no anticoagulation. Meta-analyses confirm that LMWH produces more complete recanalization than warfarin and reduces all-cause mortality.
Warfarin may be considered as an alternative if LMWH is contraindicated, though INR monitoring is problematic in cirrhosis due to baseline coagulopathy and uncertain target ranges. Historical studies have used INR targets of 2-3, but this approach requires careful individualization.
The decision to anticoagulate should be individualized based on extent of thrombosis, bleeding risk, platelet count (generally safe if more than 50,000/μL), and fall risk rather than INR alone.
Active bleeding would be a contraindication, but thrombocytopenia and prolonged INR should not automatically preclude treatment.”
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 06:29Markus Müller: ABO Blood Groups and the Rare Bombay Phenotype
-
Nov 20, 2026, 05:57Lance Reed: Specialized Blood Components and Clinical Samples for Research and Diagnostics
-
Nov 20, 2026, 05:41Sundas Anjum: Community Engagement and Blood Donation for Thalassemia Care
-
Nov 20, 2026, 05:24A Celebration of Unity and Dedication in Hemophilia Care – Hemophilia Society Mumbai Chapter
-
Nov 20, 2026, 05:09Farhad Sheikh: Prasugrel vs Ticagrelor in Acute Coronary Syndromes
-
Nov 20, 2026, 05:02Jason Acker: Appointed as the Next Editor-in-Chief of Vox Sanguinis
-
Nov 20, 2026, 04:58Sabri Kemahli: International Society of Hematology Celebrates 80 Years of Hematology with Special Webinar
-
Nov 20, 2026, 04:46Alessandra Bosch: Swiss Haemophilia Network Wins Research Grant
-
Nov 20, 2026, 04:41Courtney Lawrence: HLA Antibodies and Platelet Transfusion Refractoriness in Hispanic Patients